Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
Avita Medical Inc (RCEL) delivers breakthrough regenerative medicine solutions through its FDA-approved RECELL system, transforming wound care and skin restoration. This news hub provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative information about RCEL's innovative approach to burn treatment and skin repair, including FDA clearances, international regulatory progress, and partnerships shaping the future of point-of-care cell therapy. Our curated collection features press releases on product innovations, peer-reviewed research validations, and market expansion activities.
Key content categories include clinical trial outcomes, regulatory submissions, financial performance updates, and technological refinements to the RECELL platform. Users benefit from centralized access to verified information supporting informed analysis of this medical device innovator.
Bookmark this page for streamlined tracking of Avita Medical's progress in advancing regenerative wound care solutions. Check regularly for updates demonstrating how RCEL's patented technology continues to redefine standards in acute burn treatment and complex wound management.
AVITA Medical, Inc. (NASDAQ: RCEL) announced a poster presentation on the RECELL® System for treating stable vitiligo at an upcoming conference in Santa Barbara, CA, scheduled for August 19-21, 2022. The presentation will focus on the cell characterization and potential clinical benefits of the RECELL platform. CEO Dr. Mike Perry expressed hopes for the FDA’s review, indicating that the RECELL System could provide a significant treatment option for vitiligo patients. Additionally, AVITA is completing a pivotal trial for the RECELL System, anticipating FDA approval in 2023.
AVITA Medical reported its second quarter financial results for 2022, showing commercial revenue of $8.2 million, a 23% increase from the previous year. Total revenue, including BARDA revenue, was $8.3 million, down from $10.3 million due to a decrease in BARDA contributions. Gross profit margin improved to 83%. Year-to-date commercial revenue reached $15.7 million, up 39%. However, the net loss increased 33% to $6.3 million, and total operating expenses grew by 3%. The company projects commercial revenues of $30 million for the year, excluding BARDA revenue.
AVITA Medical announced positive topline results from its pivotal trial evaluating the RECELL System for soft tissue reconstruction, targeting donor skin harvesting reduction. The trial showed statistically superior donor sparing (p<0.001) versus conventional skin grafting. Although the healing endpoint did not achieve statistical non-inferiority, healing results were comparable. The company plans to submit a PMA supplement to the FDA by the end of 2022 and anticipates significant market potential, with a total addressable market of approximately $1 billion for soft tissue repair.
AVITA Medical (NASDAQ: RCEL) will release its second quarter 2022 financial results on August 11, 2022. A conference call and webcast are scheduled for 2:00 p.m. PT / 5:00 p.m. ET to discuss these results. AVITA Medical focuses on regenerative medicine and offers the RECELL® System for treating acute thermal burns using patients' own skin cells. This technology is FDA-approved and has shown significant improvement in clinical outcomes.
AVITA Medical (RCEL) reported financial results for Q1 2022, showing a significant 61% increase in commercial revenue to $7.4 million compared to Q1 2021. However, total revenue was $7.5 million, down from $8.8 million in the prior year due to a decline in BARDA revenue. The company reported a net loss of $9.5 million, a 58% increase from the previous year's loss. Looking ahead, AVITA expects 2022 commercial revenue of approximately $30 million, a 20% increase year-over-year, despite reduced BARDA revenues.
AVITA Medical (NASDAQ: RCEL) announced that discussions regarding the RECELL System will occur at the SCALE dermatology meeting in Nashville, TN from May 11-15, 2022. Key presentations include Dr. Jeffrey Carter discussing burn treatment and Dr. Seemal Desai reviewing a clinical trial for vitiligo treatment. AVITA is conducting a pivotal trial for stable vitiligo and aims to share topline data later this year. The RECELL System is FDA-approved for acute thermal burns and offers innovative solutions in regenerative medicine.
AVITA Medical (NASDAQ: RCEL) has announced it will release its Q1 2022 financial results on May 12, 2022, followed by a conference call at 1:30 p.m. PT. The company focuses on regenerative medicine, developing technology for autologous skin restoration to address unmet medical needs. Its RECELL® System, FDA-approved in 2018, uses a patient's skin cells for treating acute burns, showing significant advancements in clinical outcomes and cost efficiency. The live call will be accessible via telephone and the company's website.
AVITA Medical (NASDAQ: RCEL) announced the resignation of Louis Drapeau from the Board of Directors, effective April 29, 2022, citing personal reasons. Drapeau has been a non-executive Director since January 2016 and previously chaired the Audit Committee, which has now been taken over by James Corbett as of February 23, 2022. The company expressed gratitude for Drapeau's six years of service. AVITA develops regenerative medicine technologies, particularly the RECELL® System for skin restoration, approved by the FDA in September 2018.
AVITA Medical (NASDAQ: RCEL) announced 15 presentations at the American Burn Association Annual Meeting, showcasing the efficacy and cost-saving benefits of the RECELL® System for treating burn wounds. The event, taking place April 5-8 in Las Vegas, is expected to attract over 2,000 burn care professionals. With real-world application data from over 15,000 patients, the RECELL System has proven advantageous over traditional methods. AVITA aims to expand RECELL's indications beyond burns to include soft-tissue repair and vitiligo, pending FDA approval.
AVITA Medical (NASDAQ: RCEL) announced the presentation of a clinical trial protocol for the RECELL® System at the Global Vitiligo Foundation Annual Scientific Symposium. This trial aims to assess the safety and effectiveness of RECELL in treating stable vitiligo lesions. With enrollment now complete, the company anticipates releasing results from its blinded, randomized study soon. Vitiligo affects 2% of the global population, significantly impacting patients' quality of life. The RECELL System, approved by the FDA in 2018, utilizes patients' skin cells for regenerative treatments.
